Related Experiment Video

Updated: Jul 5, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway

J E Kravchenko1, G V Ilyinskaya, P G Komarov

  • 1Lerner Research Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

Proceedings of the National Academy of Sciences of the United States of America
|April 22, 2008
PubMed

Insights

A novel compound, RETRA, specifically targets and suppresses cancer cells with mutant p53 by reactivating the tumor suppressor p73. This targeted approach shows promise for cancer therapy without affecting normal cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Mutant p53 is prevalent in cancers, impairing tumor suppression and promoting malignancy by inhibiting p73.
  • Targeting mutant p53 offers a promising strategy for cancer therapy.

Purpose of the Study:

  • To identify and characterize a small molecule that specifically targets and suppresses mutant p53-bearing cancer cells.
  • To investigate the mechanism of action of the small molecule RETRA involving the p53-p73 pathway.

Main Methods:

  • In vitro and in vivo (mouse xenograft) studies were conducted to evaluate the efficacy of RETRA.
  • RNA interference (RNAi) was used to inhibit p73 and assess its role in RETRA's mechanism.
  • Gene expression analysis and protein complex studies were performed to understand RETRA's effects on p53, p73, and downstream targets.

Main Results:

  • RETRA selectively suppressed tumor cells expressing various forms of mutant p53.
  • RETRA treatment increased p73 expression and released it from the inhibitory complex with mutant p53.
  • The therapeutic effect of RETRA was dependent on p73 and did not impact normal cells.

Conclusions:

  • The small molecule RETRA effectively targets mutant p53 cancer cells by reactivating tumor suppressor functions via the p73 pathway.
  • The mutant p53-p73 complex represents a highly specific and promising therapeutic target for a significant proportion of human cancers.

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...